DUBOIS – Soon you can be spending less for some pharmaceutical prescription drugs in Pennsylvania.
This is all a part of the Inflation Reduction Act, which allows Medicare to negotiate with pharmaceutical companies for the prices of vital prescriptions.
Last week, a total of 10 prescription drugs saw a drop in price.
A list of the drugs and negotiated price is as follows.
Eliquis (used for blood clots) went from $521 dollars to $231 dollars.
Jardiance (used for Diabetes, heart failure, and kidney disease) went from $573 dollars to $197 dollars.
Xarelto (used for blood clots and artery disease) went from $517 dollars to $197 dollars.
Januvia (used for diabetes) went from $527 dollars to $113 dollars.
Farxiga (used for Diabetes, heart failure, and kidney disease) went from $556 dollars to $178.50 dollars.
Entresto (used for heart failure) went from $628 dollars to $295 dollars.
Enbrel (used for arthritis) went from $7,106 dollars to $2,355 dollars.
Imbruvica (used for blood cancers) went from $14,934 dollars to $9,319 dollars.
Stelara (used for arthritis, Crohn’s disease, and ulcerative clots) went from $13,836 dollars to $4,695 dollars.
NovoLog/Fiasp (used for diabetes) went from $495 dollars to $119 dollars.
U.S. Senator Bob Casey says that this is just the beginning, with a goal of over 100 prescribed drugs having negotiated prices and an out of pocket maximum of $2,000 dollars for Pennsylvanians.
